Tempus AI (NASDAQ:TEM) Lowered to Hold Rating by Wolfe Research

Tempus AI (NASDAQ:TEM) was downgraded by equities research analysts at Wolfe Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other analysts have also recently issued reports on the company. TD Cowen reaffirmed a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Loop Capital decreased their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Guggenheim restated a “buy” rating on shares of Tempus AI in a research note on Tuesday. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.55.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $55.30 on Wednesday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock’s fifty day moving average price is $52.29 and its 200-day moving average price is $52.27. Tempus AI has a 12 month low of $22.89 and a 12 month high of $91.45.

Insiders Place Their Bets

In related news, CAO Ryan M. Bartolucci sold 13,770 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares of the company’s stock, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of Tempus AI stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares in the company, valued at approximately $287,615,853.75. This trade represents a 39.83 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,823,701 shares of company stock worth $320,906,059.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. GF Fund Management CO. LTD. purchased a new position in Tempus AI during the fourth quarter worth approximately $108,000. Voloridge Investment Management LLC acquired a new stake in Tempus AI during the fourth quarter worth about $11,826,000. Two Sigma Advisers LP acquired a new position in Tempus AI in the 4th quarter valued at about $625,000. ProShare Advisors LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at approximately $244,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $1,034,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.